JP6738352B2 - ウイルス感染の治療及び予防のための新規なスルホンイミドイルプリノン化合物及び誘導体 - Google Patents
ウイルス感染の治療及び予防のための新規なスルホンイミドイルプリノン化合物及び誘導体 Download PDFInfo
- Publication number
- JP6738352B2 JP6738352B2 JP2017558397A JP2017558397A JP6738352B2 JP 6738352 B2 JP6738352 B2 JP 6738352B2 JP 2017558397 A JP2017558397 A JP 2017558397A JP 2017558397 A JP2017558397 A JP 2017558397A JP 6738352 B2 JP6738352 B2 JP 6738352B2
- Authority
- JP
- Japan
- Prior art keywords
- purin
- methyl
- amino
- compound
- propylsulfonimidoyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *Nc(nc(nc1N2*)S(*)(=N*)=O)c1N(*)C2=O Chemical compound *Nc(nc(nc1N2*)S(*)(=N*)=O)c1N(*)C2=O 0.000 description 3
- XJEVQCHAETXVIB-UHFFFAOYSA-N CCCCC(Nc(nc(nc1N2Cc3ccccc3)S(CCC)=O)c1NC2=O)=O Chemical compound CCCCC(Nc(nc(nc1N2Cc3ccccc3)S(CCC)=O)c1NC2=O)=O XJEVQCHAETXVIB-UHFFFAOYSA-N 0.000 description 2
- KFDGFNQIYSAVAY-UHFFFAOYSA-N CCCS(c(nc1N2Cc3ccccc3)nc(N)c1NC2=O)(=N)=O Chemical compound CCCS(c(nc1N2Cc3ccccc3)nc(N)c1NC2=O)(=N)=O KFDGFNQIYSAVAY-UHFFFAOYSA-N 0.000 description 2
- WXCATEWRWJKDJL-UHFFFAOYSA-N CCCCC(Nc(nc(nc1N2Cc3ccccc3)SCCC)c1NC2=O)=O Chemical compound CCCCC(Nc(nc(nc1N2Cc3ccccc3)SCCC)c1NC2=O)=O WXCATEWRWJKDJL-UHFFFAOYSA-N 0.000 description 1
- APBICSQRGKTYKB-UHFFFAOYSA-N CCCS(c(nc1N)nc(N2Cc3ccc(C(F)(F)F)cc3)c1NC2=O)(=N)=O Chemical compound CCCS(c(nc1N)nc(N2Cc3ccc(C(F)(F)F)cc3)c1NC2=O)(=N)=O APBICSQRGKTYKB-UHFFFAOYSA-N 0.000 description 1
- XMBWXMCTNHNBEU-UHFFFAOYSA-N CCCS(c(nc1N)nc(N2Cc3ccccc3)c1NC2=O)=O Chemical compound CCCS(c(nc1N)nc(N2Cc3ccccc3)c1NC2=O)=O XMBWXMCTNHNBEU-UHFFFAOYSA-N 0.000 description 1
- MBQBYGUMANOLRF-UHFFFAOYSA-N CCCS(c(nc1N2Cc(cc3)cc(Cl)c3Cl)nc(N)c1NC2=O)(=N)=O Chemical compound CCCS(c(nc1N2Cc(cc3)cc(Cl)c3Cl)nc(N)c1NC2=O)(=N)=O MBQBYGUMANOLRF-UHFFFAOYSA-N 0.000 description 1
- WLAWDJREXFPHPH-UHFFFAOYSA-N CCCS(c(nc1N2Cc(cc3)ccc3Cl)nc(N)c1NC2=O)(=N)=O Chemical compound CCCS(c(nc1N2Cc(cc3)ccc3Cl)nc(N)c1NC2=O)(=N)=O WLAWDJREXFPHPH-UHFFFAOYSA-N 0.000 description 1
- MSSXPOADQWRGGF-UHFFFAOYSA-N CCCS(c(nc1N2Cc(cc3)ccc3Cl)nc(NC(C(C)(C)C)=O)c1NC2=O)(=N)=O Chemical compound CCCS(c(nc1N2Cc(cc3)ccc3Cl)nc(NC(C(C)(C)C)=O)c1NC2=O)(=N)=O MSSXPOADQWRGGF-UHFFFAOYSA-N 0.000 description 1
- OMOVBYAITFNLQV-UHFFFAOYSA-N CCCS(c(nc1N2Cc(cn3)ccc3Cl)nc(N)c1NC2=O)(=N)=O Chemical compound CCCS(c(nc1N2Cc(cn3)ccc3Cl)nc(N)c1NC2=O)(=N)=O OMOVBYAITFNLQV-UHFFFAOYSA-N 0.000 description 1
- HJPNICYHBIWMIN-UHFFFAOYSA-N CCCS(c(nc1N2Cc3cc(Cl)c(C)cc3)nc(N)c1NC2=O)=O Chemical compound CCCS(c(nc1N2Cc3cc(Cl)c(C)cc3)nc(N)c1NC2=O)=O HJPNICYHBIWMIN-UHFFFAOYSA-N 0.000 description 1
- YXFJJQUVGAPZKB-UHFFFAOYSA-N CCCS(c(nc1N2Cc3ccc(C)cc3)nc(N)c1NC2=O)(=N)=O Chemical compound CCCS(c(nc1N2Cc3ccc(C)cc3)nc(N)c1NC2=O)(=N)=O YXFJJQUVGAPZKB-UHFFFAOYSA-N 0.000 description 1
- AOIPJFRADPKAFS-UHFFFAOYSA-N CCCS(c(nc1N2Cc3ccc(C)nc3)nc(NCC)c1NC2=O)=O Chemical compound CCCS(c(nc1N2Cc3ccc(C)nc3)nc(NCC)c1NC2=O)=O AOIPJFRADPKAFS-UHFFFAOYSA-N 0.000 description 1
- LHRAYRPXCNIOOH-UHFFFAOYSA-N CCCS(c(nc1N2Cc3ccccc3)nc(N)c1N(C(C)OC(C)=O)C2=O)(=N)=O Chemical compound CCCS(c(nc1N2Cc3ccccc3)nc(N)c1N(C(C)OC(C)=O)C2=O)(=N)=O LHRAYRPXCNIOOH-UHFFFAOYSA-N 0.000 description 1
- TWWIKYSVNRCTOK-UHFFFAOYSA-N CCCS(c(nc1N2Cc3ccccc3)nc(NCC)c1NC2=O)=O Chemical compound CCCS(c(nc1N2Cc3ccccc3)nc(NCC)c1NC2=O)=O TWWIKYSVNRCTOK-UHFFFAOYSA-N 0.000 description 1
- POOOKUXMUVRWEZ-UHFFFAOYSA-N CCCSc(nc1Cl)nc(NCc(cc2)cc(C)c2Cl)c1N Chemical compound CCCSc(nc1Cl)nc(NCc(cc2)cc(C)c2Cl)c1N POOOKUXMUVRWEZ-UHFFFAOYSA-N 0.000 description 1
- YEOAWWOBFYFPBW-UHFFFAOYSA-N CCCSc(nc1N)nc(N2Cc(cc3)ccc3Br)c1NC2=O Chemical compound CCCSc(nc1N)nc(N2Cc(cc3)ccc3Br)c1NC2=O YEOAWWOBFYFPBW-UHFFFAOYSA-N 0.000 description 1
- FBFBHKHVBSHQDY-UHFFFAOYSA-N CCCSc(nc1N2Cc(cc3)ccc3Cl)nc(N)c1NC2=O Chemical compound CCCSc(nc1N2Cc(cc3)ccc3Cl)nc(N)c1NC2=O FBFBHKHVBSHQDY-UHFFFAOYSA-N 0.000 description 1
- WSLPWOKZOATGMZ-UHFFFAOYSA-N CCCSc(nc1N2Cc(cc3)ccc3Cl)nc(NC(C)=O)c1NC2=O Chemical compound CCCSc(nc1N2Cc(cc3)ccc3Cl)nc(NC(C)=O)c1NC2=O WSLPWOKZOATGMZ-UHFFFAOYSA-N 0.000 description 1
- HMWSWNCISULJJJ-UHFFFAOYSA-N CCCSc(nc1N2Cc3cc(Cl)c(C)cc3)nc(N)c1NC2=O Chemical compound CCCSc(nc1N2Cc3cc(Cl)c(C)cc3)nc(N)c1NC2=O HMWSWNCISULJJJ-UHFFFAOYSA-N 0.000 description 1
- SRNUMMPVJTYPCV-UHFFFAOYSA-N CCCSc(nc1N2Cc3cc(N)ccc3)nc(N)c1NC2=O Chemical compound CCCSc(nc1N2Cc3cc(N)ccc3)nc(N)c1NC2=O SRNUMMPVJTYPCV-UHFFFAOYSA-N 0.000 description 1
- SAZWABVFGVSDDB-UHFFFAOYSA-N CCCSc(nc1N2Cc3cccc(N)c3)nc(Cl)c1NC2=O Chemical compound CCCSc(nc1N2Cc3cccc(N)c3)nc(Cl)c1NC2=O SAZWABVFGVSDDB-UHFFFAOYSA-N 0.000 description 1
- MCBGAVARLDFVPY-UHFFFAOYSA-N CCCSc(nc1N2Cc3ccccc3)nc(N)c1NC2=O Chemical compound CCCSc(nc1N2Cc3ccccc3)nc(N)c1NC2=O MCBGAVARLDFVPY-UHFFFAOYSA-N 0.000 description 1
- FDLQLLZNIHGIRR-UHFFFAOYSA-N CCCSc(nc1NCc(cc2)cc(Cl)c2Cl)nc(Cl)c1[N+]([O-])=O Chemical compound CCCSc(nc1NCc(cc2)cc(Cl)c2Cl)nc(Cl)c1[N+]([O-])=O FDLQLLZNIHGIRR-UHFFFAOYSA-N 0.000 description 1
- TWTXTWSFXYSAGO-UHFFFAOYSA-N CCCSc(nc1NCc(cc2)ccc2Br)nc(Cl)c1[N+]([O-])=O Chemical compound CCCSc(nc1NCc(cc2)ccc2Br)nc(Cl)c1[N+]([O-])=O TWTXTWSFXYSAGO-UHFFFAOYSA-N 0.000 description 1
- KUISQZDVMKSVNP-UHFFFAOYSA-N CCCSc(nc1NCc(cc2)ccc2S(C)(=O)=O)nc(Cl)c1[N+]([O-])=O Chemical compound CCCSc(nc1NCc(cc2)ccc2S(C)(=O)=O)nc(Cl)c1[N+]([O-])=O KUISQZDVMKSVNP-UHFFFAOYSA-N 0.000 description 1
- BRSQFEYCEJEYCJ-UHFFFAOYSA-N CCS(c(nc1N2Cc3ccc(C)cc3)nc(N)c1NC2=O)(=N)=O Chemical compound CCS(c(nc1N2Cc3ccc(C)cc3)nc(N)c1NC2=O)(=N)=O BRSQFEYCEJEYCJ-UHFFFAOYSA-N 0.000 description 1
- LHRSFBRLPAJSMK-UHFFFAOYSA-N CCSc(nc1N2Cc3ccc(C)cc3)nc(N)c1NC2=O Chemical compound CCSc(nc1N2Cc3ccc(C)cc3)nc(N)c1NC2=O LHRSFBRLPAJSMK-UHFFFAOYSA-N 0.000 description 1
- RKOAQZHSBQHMDM-UHFFFAOYSA-N COCCS(c(nc1N2Cc3ccccc3)nc(N)c1NC2=O)=O Chemical compound COCCS(c(nc1N2Cc3ccccc3)nc(N)c1NC2=O)=O RKOAQZHSBQHMDM-UHFFFAOYSA-N 0.000 description 1
- GJZZDPHTUXZRDP-UHFFFAOYSA-N CS(c(nc1N2Cc3ccccc3)nc(N)c1NC2=O)(=N)=O Chemical compound CS(c(nc1N2Cc3ccccc3)nc(N)c1NC2=O)(=N)=O GJZZDPHTUXZRDP-UHFFFAOYSA-N 0.000 description 1
- OWHOVQKHZCNMAL-UHFFFAOYSA-N CSc(nc1N2Cc3cccnc3)nc(N)c1NC2=O Chemical compound CSc(nc1N2Cc3cccnc3)nc(N)c1NC2=O OWHOVQKHZCNMAL-UHFFFAOYSA-N 0.000 description 1
- FAVREULOXHXCQX-UHFFFAOYSA-N Cc(cc(CN)cc1)c1Cl Chemical compound Cc(cc(CN)cc1)c1Cl FAVREULOXHXCQX-UHFFFAOYSA-N 0.000 description 1
- NZPFQOXRHLUPRT-UHFFFAOYSA-N Cc1ncc(CN)cc1 Chemical compound Cc1ncc(CN)cc1 NZPFQOXRHLUPRT-UHFFFAOYSA-N 0.000 description 1
- JJNLGGQLCGZEIB-UHFFFAOYSA-N NC(N1Cc2ccccc2)=C(C#N)NC1=O Chemical compound NC(N1Cc2ccccc2)=C(C#N)NC1=O JJNLGGQLCGZEIB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2015/078507 | 2015-05-08 | ||
| CN2015078507 | 2015-05-08 | ||
| CN2016078785 | 2016-04-08 | ||
| CNPCT/CN2016/078785 | 2016-04-08 | ||
| PCT/EP2016/059961 WO2016180695A1 (en) | 2015-05-08 | 2016-05-04 | Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018515509A JP2018515509A (ja) | 2018-06-14 |
| JP2018515509A5 JP2018515509A5 (https=) | 2020-06-18 |
| JP6738352B2 true JP6738352B2 (ja) | 2020-08-12 |
Family
ID=55910966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017558397A Active JP6738352B2 (ja) | 2015-05-08 | 2016-05-04 | ウイルス感染の治療及び予防のための新規なスルホンイミドイルプリノン化合物及び誘導体 |
Country Status (32)
| Country | Link |
|---|---|
| US (3) | US9708325B2 (https=) |
| EP (1) | EP3294740B1 (https=) |
| JP (1) | JP6738352B2 (https=) |
| KR (1) | KR102690131B1 (https=) |
| CN (1) | CN107580596B (https=) |
| AR (1) | AR104528A1 (https=) |
| AU (3) | AU2016260683B2 (https=) |
| BR (1) | BR112017023959B1 (https=) |
| CA (1) | CA2982704C (https=) |
| CL (1) | CL2017002745A1 (https=) |
| CO (1) | CO2017009994A2 (https=) |
| CR (1) | CR20170496A (https=) |
| DK (1) | DK3294740T3 (https=) |
| ES (1) | ES2753777T3 (https=) |
| HR (1) | HRP20191942T1 (https=) |
| HU (1) | HUE045906T2 (https=) |
| IL (2) | IL254947B (https=) |
| LT (1) | LT3294740T (https=) |
| MX (2) | MX376761B (https=) |
| MY (1) | MY182353A (https=) |
| NZ (2) | NZ775222A (https=) |
| PE (1) | PE20171620A1 (https=) |
| PH (1) | PH12017502009A1 (https=) |
| PL (1) | PL3294740T3 (https=) |
| PT (1) | PT3294740T (https=) |
| RS (1) | RS59435B1 (https=) |
| RU (1) | RU2745269C2 (https=) |
| SG (1) | SG10202108841YA (https=) |
| SI (1) | SI3294740T1 (https=) |
| TW (2) | TWI706954B (https=) |
| UA (1) | UA120450C2 (https=) |
| WO (1) | WO2016180695A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3294740T3 (pl) * | 2015-05-08 | 2020-03-31 | F. Hoffmann-La Roche Ag | Nowe sulfonoimidoilopurynony i pochodne do leczenia i profilaktyki infekcji wirusowych |
| AU2017320742B2 (en) | 2016-08-29 | 2021-08-05 | F. Hoffmann-La Roche Ag | 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection |
| CN109715214B (zh) | 2016-09-13 | 2022-03-04 | 豪夫迈·罗氏有限公司 | Tlr7激动剂和hbv衣壳组装抑制剂的组合治疗 |
| JP7328977B2 (ja) | 2018-02-12 | 2023-08-17 | エフ． ホフマン－ラ ロシュ アーゲー | ウイルス感染の処置および予防のための新規のスルホン化合物および誘導体 |
| RU2020131012A (ru) * | 2018-02-28 | 2022-03-28 | Ф. Хоффманн-Ля Рош Аг | 7-замещенные соединения сульфонимидоилпуринонов и их производные для лечения и профилактики рака печени |
| CN111072667A (zh) * | 2018-10-22 | 2020-04-28 | 罗欣药业(上海)有限公司 | 五元或六元杂环并嘧啶类化合物及其用途 |
| JP7695885B2 (ja) * | 2019-02-12 | 2025-06-19 | アンブルックス，インコーポレイテッド | 抗体－ｔｌｒアゴニストコンジュゲートを含有する組成物、その方法、及び使用 |
| JP7581336B2 (ja) | 2019-09-20 | 2024-11-12 | シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト | 硫黄及びスルホキシミン含有置換基を有する殺有害生物的に活性な複素環式誘導体 |
| US20230131192A1 (en) * | 2020-01-27 | 2023-04-27 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
| JP2023512204A (ja) * | 2020-01-27 | 2023-03-24 | ブリストル－マイヤーズ スクイブ カンパニー | トール様受容体７（ＴＬＲ７）アゴニストとしての１Ｈ－ピラゾロ［４，３－ｄ］ピリミジン化合物 |
| CN119604517A (zh) | 2022-07-14 | 2025-03-11 | 豪夫迈·罗氏有限公司 | 用于治疗癌症的磷酰基嘌呤酮化合物 |
| CN118724963A (zh) * | 2023-03-30 | 2024-10-01 | 浙江养生堂天然药物研究所有限公司 | 含磷或含硫的大环化合物及其用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4189048B2 (ja) * | 1997-12-26 | 2008-12-03 | 大日本住友製薬株式会社 | 複素環化合物 |
| EP1888587A1 (en) | 2005-05-04 | 2008-02-20 | Pfizer Limited | 2-amido-6-amino-8-oxopurine derivatives as toll-like receptor modulators for the treatment of cancer and viral infections, such as hepatitis c |
| CN101239980B (zh) | 2008-02-18 | 2011-06-22 | 靳广毅 | 免疫受体调节剂偶联体前体和偶联体及其应用 |
| ES2467108T3 (es) * | 2008-12-09 | 2014-06-11 | Gilead Sciences, Inc. | Moduladores de receptores tipo toll |
| WO2011079016A1 (en) | 2009-12-22 | 2011-06-30 | Gilead Sciences, Inc. | Methods of treating hbv and hcv infection |
| TW201636330A (zh) * | 2011-05-24 | 2016-10-16 | 拜耳知識產權公司 | 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺 |
| RS57851B1 (sr) * | 2011-11-09 | 2018-12-31 | Janssen Sciences Ireland Uc | Purinski derivati za tretman viralnih infekcija |
| AU2014242954B2 (en) | 2013-03-29 | 2018-03-15 | Janssen Sciences Ireland Uc | Macrocyclic deaza-purinones for the treatment of viral infections |
| HUE054672T2 (hu) | 2014-08-15 | 2021-09-28 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | TLR7 agonistaként alkalmazott pirrolopirimidin vegyületek |
| PL3294740T3 (pl) * | 2015-05-08 | 2020-03-31 | F. Hoffmann-La Roche Ag | Nowe sulfonoimidoilopurynony i pochodne do leczenia i profilaktyki infekcji wirusowych |
| AU2017320742B2 (en) * | 2016-08-29 | 2021-08-05 | F. Hoffmann-La Roche Ag | 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection |
-
2016
- 2016-05-04 PL PL16720421T patent/PL3294740T3/pl unknown
- 2016-05-04 RU RU2017142577A patent/RU2745269C2/ru active
- 2016-05-04 BR BR112017023959-0A patent/BR112017023959B1/pt not_active IP Right Cessation
- 2016-05-04 SG SG10202108841YA patent/SG10202108841YA/en unknown
- 2016-05-04 NZ NZ775222A patent/NZ775222A/en unknown
- 2016-05-04 MY MYPI2017704175A patent/MY182353A/en unknown
- 2016-05-04 AU AU2016260683A patent/AU2016260683B2/en not_active Ceased
- 2016-05-04 CA CA2982704A patent/CA2982704C/en active Active
- 2016-05-04 DK DK16720421T patent/DK3294740T3/da active
- 2016-05-04 PT PT167204213T patent/PT3294740T/pt unknown
- 2016-05-04 UA UAA201712023A patent/UA120450C2/uk unknown
- 2016-05-04 MX MX2017014033A patent/MX376761B/es active IP Right Grant
- 2016-05-04 ES ES16720421T patent/ES2753777T3/es active Active
- 2016-05-04 PE PE2017002102A patent/PE20171620A1/es unknown
- 2016-05-04 KR KR1020177035298A patent/KR102690131B1/ko active Active
- 2016-05-04 WO PCT/EP2016/059961 patent/WO2016180695A1/en not_active Ceased
- 2016-05-04 CN CN201680026493.3A patent/CN107580596B/zh active Active
- 2016-05-04 HU HUE16720421A patent/HUE045906T2/hu unknown
- 2016-05-04 EP EP16720421.3A patent/EP3294740B1/en active Active
- 2016-05-04 HR HRP20191942TT patent/HRP20191942T1/hr unknown
- 2016-05-04 JP JP2017558397A patent/JP6738352B2/ja active Active
- 2016-05-04 SI SI201630473T patent/SI3294740T1/sl unknown
- 2016-05-04 LT LT16720421T patent/LT3294740T/lt unknown
- 2016-05-04 RS RSP20191351 patent/RS59435B1/sr unknown
- 2016-05-04 MX MX2020010949A patent/MX393198B/es unknown
- 2016-05-04 CR CR20170496A patent/CR20170496A/es unknown
- 2016-05-04 NZ NZ735648A patent/NZ735648A/en not_active IP Right Cessation
- 2016-05-05 AR ARP160101278A patent/AR104528A1/es unknown
- 2016-05-06 TW TW105114192A patent/TWI706954B/zh active
- 2016-05-06 TW TW109131169A patent/TWI768467B/zh not_active IP Right Cessation
- 2016-05-06 US US15/148,309 patent/US9708325B2/en active Active
-
2017
- 2017-06-13 US US15/621,080 patent/US10399983B2/en active Active
- 2017-09-29 CO CONC2017/0009994A patent/CO2017009994A2/es unknown
- 2017-10-09 IL IL254947A patent/IL254947B/en active IP Right Grant
- 2017-10-30 CL CL2017002745A patent/CL2017002745A1/es unknown
- 2017-11-03 PH PH12017502009A patent/PH12017502009A1/en unknown
-
2019
- 2019-08-02 US US16/530,229 patent/US11242345B2/en active Active
-
2020
- 2020-10-14 AU AU2020256348A patent/AU2020256348B2/en not_active Ceased
-
2021
- 2021-02-09 IL IL280769A patent/IL280769B2/en unknown
-
2022
- 2022-06-29 AU AU2022204666A patent/AU2022204666A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6738352B2 (ja) | ウイルス感染の治療及び予防のための新規なスルホンイミドイルプリノン化合物及び誘導体 | |
| KR102030305B1 (ko) | 키나제 억제제로서 유용한 인돌 카르복스아미드 화합물 | |
| CN101983191B (zh) | 作为hsp90抑制剂的肟衍生物 | |
| TW201623256A (zh) | 非核苷反轉錄酶抑制劑 | |
| BRPI0619704A2 (pt) | composto, composição, método para inibir a atividade da proteìna aurora quinase numa amostra biológica, método para tratar um distúrbio proliferativo e método para tratar cáncer | |
| JP6888000B2 (ja) | 新規な修飾された大環状化合物 | |
| CA3057891A1 (en) | Novel ptefb inhibiting macrocyclic compounds | |
| CN118525020A (zh) | 具有clk和dyrk抑制活性的化合物、其制备方法及用途 | |
| CN114450277A (zh) | 用于治疗和预防乙型肝炎病毒感染的经取代的嘧啶 | |
| HK1247925B (zh) | 用於治疗和预防病毒感染的新的磺亚氨酰基嘌呤酮化合物和衍生物 | |
| CN117715911A (zh) | 癌症治疗中的n6-腺苷-甲基转移酶抑制剂 | |
| HK40067638A (en) | Substituted pyrimidine for the treatment and prophylaxis of hepatitis b virus infection | |
| CN107406452B (zh) | 吡唑并[3,4-d]嘧啶衍生物及其治疗利什曼病的用途 | |
| HK40002185A (en) | Novel pyrazine compounds with oxygen, sulfur and nitrogen linker for the treatment of infectious diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190425 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200213 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200213 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200428 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20200428 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200707 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200717 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6738352 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |